Evidence map›Paper›PMID 32518596›Full record

ArticleTherapeutic advances in medical oncology2020

Early identification of treatment benefit by methylated circulating tumor DNA in metastatic colorectal cancer.

Caroline B Thomsen, Torben F Hansen, Rikke F Andersen, Jan Lindebjerg, Lars H Jensen, Anders Jakobsen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Cancers · 2022
    Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Caroline B ThomsenDanish Colorectal Cancer Center South, Vejle University Hospital, Beriderbakken 4, DK-7100 Vejle, Denmark.ORCID https://orcid.org/0000-0003-4481-6274
Torben F HansenDanish Colorectal Cancer Center South, Vejle University Hospital, Vejle, Denmark Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.
Rikke F AndersenDanish Colorectal Cancer Center South, Vejle University Hospital, Vejle, Denmark.
Jan LindebjergDanish Colorectal Cancer Center South, Vejle University Hospital, Vejle, Denmark Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.
Lars H JensenDanish Colorectal Cancer Center South, Vejle University Hospital, Vejle, Denmark Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.
Anders JakobsenDanish Colorectal Cancer Center South, Vejle University Hospital, Vejle, Denmark Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.
University of Southern Denmark · DKVejle Sygehus · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe early identification of treatment effect is wanted in several settings, including the management of metastatic colorectal cancer (mCRC). A potential universal marker is circulating tumor DNA (ctDNA). Our prospective study explored the association between progression-free survival (PFS) and overall survival (OS), and early change of ctDNA after one cycle of chemotherapy in patients with mCRC.

methodsThe study included mCRC patients receiving standard first line combination chemotherapy with 5-Fluorouracil (FU), oxaliplatin, and bevacizumab. Hypermethylated neuropeptide Y (NPY) ctDNA (meth-ctDNA) served as a marker analyzed by droplet digital polymerase chain reaction (PCR). The meth-ctDNA level was analyzed in plasma before treatment start and again before cycle two. The patients were divided into two groups according to the dynamics of meth-ctDNA. Low ctDNA (LctDNA) included patients with zero or values of meth-ctDNA decreasing to a level including zero in the 95% confidence interval. High ctDNA (HctDNA) included all other patients (stable, increasing, or slightly decreasing values). The two groups were compared as to PFS and OS.

resultsThe study included 123 patients. The PFS in the two groups differed significantly with a median of 9.2 and 6.7 months in LctDNA and HctDNA, respectively (

conclusionsEarly therapeutic reconsideration is of utmost importance. A low level of meth-ctDNA after one cycle of chemotherapy in the first line setting is a potential marker for excellent clinical outcomes. The clinical utility should be confirmed in randomized clinical trials.

Indexed as

blood-based biomarkercolorectal cancerdrug resistanceliquid biopsyprognostic biomarker

Identifiers

PMID32518596
PMCPMC7252368
OpenAlexW3029580909

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.